RxDoctor Payments Data

Richard Pekala, MD

General Practice · Kailua Kona, HINPI 1336174341

Payments from drug & device makers

$2,456in general payments, 2019–2025

Across 124 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$641
  • Novo Nordisk$485
  • Boehringer Ingelheim$300
  • Pfizer$246
  • AstraZeneca$127
  • Amarin Pharma, Inc.$119
  • plus $537 from 8 others

What the payments were for

  • Food & beverage$2,44199%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,456 in reported general payments places this provider in the 85th percentile of 650 general practice providers in Hawaii.

See all general practice providers in Hawaii

Medicare billing

Part B allowed, 2024
$79,687
Medicare patients
171
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate81$90,329
OzempicSemaglutide35$56,437
JardianceEmpagliflozin30$42,005
RybelsusSemaglutide14$38,893
Breo ElliptaFluticasone/Vilanterol34$20,780
Atorvastatin Calcium511$19,233
EliquisApixaban11$17,714
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$17,331
Repatha SureclickEvolocumab20$12,998
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$9,541
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,772
Arnuity ElliptaFluticasone Furoate24$6,246
Rosuvastatin Calcium85$5,554
MovantikNaloxegol Oxalate13$5,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$485$95,33149 claims
MerckJanuvia$59$90,32981 claims
Boehringer IngelheimJardiance$300$42,00530 claims
PfizerEliquis$246$17,71411 claims
Teva Pharmaceuticals USA, Inc.Proair Respiclick$115$1,14417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 650 general practice providers in Hawaii.

Other general practice in Kailua Kona

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →